Vaccines

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

A global consortium pioneers new drugs designed specifically for children, moving away from harsh adult treatments for aggressive pediatric cancers.

OSE Immunotherapeutics confirms Marc Le Bozec as CEO, betting on his turnaround expertise to navigate market pressures and commercialize its key therapies.

A new line of ultra-pure proteins with endotoxin levels 10x below the standard could revolutionize advanced therapies and fix a key source of error in science.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

A new trial in China tests a dual-action antibody for esophageal cancer, a top killer. The therapy aims to unleash a two-pronged immune attack on tumors.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

New preclinical data shows Quanta Therapeutics' inhibitors remain potent against cancers that have developed resistance to advanced pan-RAS treatments.

Taiwanese biotech GNTbm's oral drug GNTbm-38, which turns 'cold' tumors 'hot', will begin Phase 1 trials for advanced and refractory cancers.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

Beyond the prescription pad, a new concierge program in Tucson integrates advanced diagnostics and lifestyle coaching to redefine sustainable weight management.